Geron Corporation

431 articles about Geron Corporation

• Geron Corporation Announces Appointment of Faye Feller, M.D. to Chief Medical Officer and Transition of Aleksandra Rizo, M.D., Ph.D. to Senior Advisor Role

  6/15/2022

  Geron Corporation, a late-stage clinical biopharmaceutical company, announced the appointment of Faye Feller, M.D., to Executive Vice President and Chief Medical Officer, effective July 9, 2022.

• Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 19, 2022

  5/19/2022

  Geron Corporation reported that it has granted non-statutory stock options to purchase an aggregate of 327,400 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

• Geron to Present at the H.C. Wainwright Global Investment Conference - May 17, 2022

  5/17/2022

  Geron Corporation, a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, plans to present a company overview at the H.C. Wainwright Global Investment Conference.

• Geron Corporation Reports First Quarter 2022 Financial Results

  5/9/2022

  Geron Corporation, a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, reported financial results for the first quarter of 2022, including current and projected financial resources.

• Geron to Announce First Quarter 2022 Financial Results on May 9, 2022

  5/2/2022

  Geron Corporation announced that it will release its first quarter 2022 financial results after the market closes on Monday, May 9, 2022 via press release, which will be available on the Company’s website at www.geron.com/investors.

• Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 21, 2022

  4/21/2022

  Geron Corporation reported that it has granted non-statutory stock options to purchase an aggregate of 505,800 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

• Geron to Present at the 21st Annual Needham Virtual Healthcare Conference

  4/6/2022

  Geron Corporation announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, plans to present a company overview at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13, 2022 at 3:45 p.m. ET.

• Geron Corporation Announces the Closing of its Public Offering of Common Stock and Warrants - Apr 01, 2022

  4/1/2022

  Geron Corporation, a late-stage clinical biopharmaceutical company, announced the closing of its previously announced underwritten public offering of 53,333,334 shares of its common stock and pre-funded warrants to purchase 18,095,238 shares of common stock, together with accompanying warrants to purchase 35,714,286 shares of common stock.

• Geron Corporation Announces the Pricing of its Public Offering of Common Stock and Warrants

  3/30/2022

  Geron Corporation, a late-stage clinical biopharmaceutical company, announced the pricing of its previously announced underwritten public offering of 53,333,334 shares of its common stock and pre-funded warrants to purchase 18,095,238 shares of its common stock, together with accompanying warrants to purchase 35,714,286 shares of its common stock.

• Geron Corporation Announces Proposed Public Offering of Common Stock and Warrants

  3/29/2022

  Geron Corporatio announced that it intends to offer and sell shares of its common stock, or for certain investors that so choose, in lieu of shares of its common stock, pre-funded warrants to purchase shares of its common stock, together with accompanying warrants to purchase shares of its common stock in an underwritten public offering.

• Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Mar 17, 2022

  3/17/2022

  Geron Corporation reported that it has granted non-statutory stock options to purchase an aggregate of 320,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

• Geron Corporation Reports Fourth Quarter and Full Year 2021 Financial Results and Upcoming Milestones

  3/10/2022

  Geron Corporation, a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, reported business updates, upcoming milestones and financial results for the fourth quarter and year ended December 31, 2021.

• Geron to Announce Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022

  3/3/2022

  Geron Corporation (Nasdaq: GERN) today announced that it will release its fourth quarter and full year 2021 financial results after the market closes on Thursday, March 10, 2022.

• Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Jan 20, 2022

  1/20/2022

  Geron Corporation reported that it has granted non-statutory stock options to purchase an aggregate of 435,800 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

• Geron to Present at the H.C. Wainwright BioConnect Conference

  1/4/2022

  Geron Corporation announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright BioConnect Conference.

• Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Dec 16, 2021

  12/16/2021

  Geron Corporation reported that it has granted a non-statutory stock option to purchase an aggregate of 50,000 shares of Geron common stock as an inducement to a newly hired employee in connection with commencement of employment with the Company.

• Geron Reports Presentations at American Society of Hematology Annual Meeting

  12/14/2021

  Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced three poster presentations related to imetelstat, the Company’s first in class telomerase inhibitor, at the 63rd American Society of Hematology (ASH) Annual Meeting.

• Geron Announces Appointment of Chief Business Officer

  12/2/2021

  Geron Corporation today announced the appointment of Edward Koval as Executive Vice President and Chief Business Officer.

• Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Nov 18, 2021

  11/18/2021

  Geron Corporation reported that it has granted a non-statutory stock option to purchase an aggregate of 80,000 shares of Geron common stock as an inducement to a newly hired employee in connection with commencement of employment with the Company.

• Geron to Present at the Stifel 2021 Virtual Healthcare Conference

  11/12/2021

  Geron Corporation today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, will present a company overview at the Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16, 2021 at 2:40 p.m. ET.